Ethnobridging Clinical Study in Diabetes Announced to Combat Disease Prevalence in China
COSTA MESA, Calif., Aug. 16, 2013 /PRWeb/ — WCCT Global, a contract research organization headquartered in Southern California, announced a plan for a diabetes ethnobridging clinical study with a focus aimed to support China-based pharmaceutical companies. WCCT Global has been an industry leader in helping sponsors from Asia to initiate their new product development programs in the US. And now that China is becoming the country with the highest population of T2DM in the world, WCCT Global is placing an emphasis on supporting the Chinese Pharma Industry in the development of new T2DM drugs for China and exportation to other markets worldwide. WCCT Global has extensive research experience in both ethnobridging clinical study and T2DM clinical research and is the worldwide market leader in conducting ethnic sensitivity studies in various Asian populations.
WCCT Global is located in Southern California which is richly populated by many diverse populations. However, 17% of all Asian Americans are living in Southern California, making it the largest Asian population in the U.S. Therefore, WCCT Global can reach out to Japanese, Chinese, Korean, Vietnamese, Philippine, and Taiwanese and screen large numbers for either healthy volunteer or patient studies. WCCT Global’s VP of Business Development Talia Nikolao stated, “Our capabilities in conducting an ethnobridging clinical study is the reason why many of our clients come back time and time again to have WCCT Global conduct their clinical studies.”
Ethnobridging studies are an important facet of clinical research in that they can help to expedite the drug approval process, saving months and even years of time due to the fact that the IND has been tested in a population which directly mirrors that of groups from other countries. Conducting an ethnobridging clinical study is a method used by many sponsors to save time and money during the lengthy drug approval process and limited time available to make use of patent times.